Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator\'s choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting.
Epistemonikos ID: ec159de59f9e888b45ecc4db9e5dde2752c10d96
First added on: May 07, 2024